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Abstract
Adult wound healing can result in fibrotic scarring (FS) characterized by excess expression of myofibroblasts and increased 
type I/type III collagen expression. In contrast, fetal wound healing results in complete regeneration without FS, and the 
mechanism remains unclear. Amniotic fluid cells could contribute to scar-free wound healing, but the effects of human 
amniotic fluid cells are not well characterized. Here, we determined the effect of human amniotic fluid stem cells (hAFS) 
on FS during wound healing. Human amniotic fluid was obtained by amniocentesis at 15–17 weeks of gestation. CD117-
positive cells were isolated and defined as hAFS. hAFS (1 × 106) suspended in PBS or cell-free PBS were injected around 
wounds created in the dorsal region of BALB/c mice. Wound size was macroscopically measured, and re-epithelialization 
in the epidermis, granulation tissue area in the dermis and collagen contents in the regenerated wound were histologically 
analyzed. The ability of hAFS to engraft in the wound was assessed by tracking hAFS labeled with PKH-26. hAFS fulfilled 
the minimal criteria for mesenchymal stem cells. hAFS injection into the wound accelerated wound closure via enhancement 
of re-epithelialization with less FS. The process was characterized by lower numbers of myofibroblasts and higher expression 
of type III collagen. Finally, transplanted hAFS were clearly observed in the dermis until day 7 implying that hAFS worked 
in a paracrine manner. hAFS can function in a paracrine manner to accelerate cutaneous wound healing, producing less FS, 
a process resembling fetal wound healing.
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Introduction
Cutaneous wound healing is a complex process that involves 
inflammation, cell proliferation, differentiation, migration, 
angiogenesis and remodeling of the extracellular matrix 
(ECM) [1]. It requires the cooperation of multiple cell types, 
cytokines and ECM proteins. There are phenotypic differ-
ences between the collagen components in fetal and adult 
wounds [2–6]. In adults, it sometimes results in a non-func-
tional mass of fibrotic tissue at the site of the regenerated 
tissue (a scar), characterized by abnormal ECM remodeling 
such as excessive deposition of type I collagen [7]. In con-
trast, fetal wound healing results in complete regeneration 
without fibrotic scarring, characterized by rapid deposition 
of type III collagen in a fine reticular network [2–6]. The 
factors responsible for scarless fetal wound healing have 
been attributed to intrinsic factors in the developing fetal 
dermis secondary to gene expression associated with the 
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development of fetal skin [2, 3]. However, the extrinsic fac-
tors responsible for scar-free fetal wound healing remain to 
be determined. Significantly, several studies suggested that 
the extrinsic factors in amniotic fluid and/or amniotic fluid 
cells contribute to scarless fetal wound healing [3, 8].
Mesenchymal stem cells (MSCs) are emerging as a prom-
ising cell population for the promotion of wound healing 
and their therapeutic potential depends on the origin of the 
MSC [9–11]. Among the different sources of MSCs, those 
derived from amniotic fluid have a number of characteristics 
that make them attractive candidates for stem cell therapy 
for neonates [12, 13]. Amniotic cells can be easily collected 
during routine prenatal testing and could be saved for future 
stem cell therapy, as needed. Amniotic cells are not subject 
to ethical debates because the residual amniotic fluid remain-
ing after genetic research is normally destroyed [12–14]. 
However, few studies have focused on the therapeutic effects 
of human amniotic fluid stem cells (hAFS) on wound heal-
ing, especially on ECM remodeling.
The aim of this study was to determine the effect of hAFS 
on fibrotic scarring during wound healing. Towards that end, 
we injected hAFS around a dorsal lesion in BALB/c mice 
and evaluated ECM remodeling in the regenerated tissue 
during wound healing.
Materials and methods
Isolation and culture of  CD117+ amniotic fluid cells
The study was approved by the institutional review board 
of Keio University School of Medicine (No. 20140285) and 
informed consent was obtained from all patients in writing. 
Patients were all adults. Five-milliliter samples of amniotic 
fluid were obtained from pregnant women who underwent 
amniocentesis at 15–17 weeks of gestation. Within 2 h, 
amniotic fluid samples were centrifuged at 1500 rpm for 
5 min. After removal of the supernatant, the cells were cul-
tured at 37 °C in a humidified incubator containing 5%  CO2. 
Amniotic fluid cell culture medium was composed of mini-
mum essential medium (a-MEM; Gibco, Langley, OK, USA) 
supplemented with 20% Chang Medium (18% Chang B plus 
2%Chang C; Irvine Scientific, Santa Ana, CA, USA), fetal 
bovine serum (FBS) (BioWest, Miami, FL, USA), 1% glu-
tamine (GIBCO) and 1% penicillin/streptomycin (Wako Pure 
Chemical, Osaka, Japan). For further selection of stem cell 
populations, growth medium was replaced every 4 days until 
the cell population became sub-confluent. Subsequently, 
CD117-positive (CD  117+) cells were isolated by a mag-
netic cell-sorting kit (Miltenyi Biotec, Auburn, CA, USA), 
as previously reported [12].  CD117+ cells were plated and 
expanded to higher passages for further analysis.
Immunophenotypic analysis of  CD117+ amniotic 
fluid cells
CD117+ cells were characterized by flow cytometry for sur-
face markers of mesenchymal (CD29, CD73, and CD90) 
and hematopoietic (CD14, CD34, and HLA-DR) stem cells. 
A total of 1 × 105 cells were harvested and incubated with 
either PE, FITC or APC-conjugated antibodies against 
CD29, CD73, CD90, CD14, CD34, and HLA-DR mouse 
anti-human monoclonal antibodies and appropriate isotype 
controls. Stained cells were then analyzed using a MoFlo 
XDP flow cytometer (Beckman Coulter, Inc., Brea, CA, 
USA) using Cell Quest software, and data were analyzed 
using Summit software. Antibody information is listed in 
Table 1.
Analysis of the differentiation potential of  CD117+ 
amniotic fluid cells
To investigate the differentiation capacity of hAFS,  CD117+ 
cells were differentiated in vitro into osteogenic, adipogenic, 
chondrogenic, neurogenic and cardiomyogenic lineages. 
 CD117+ cells were cultured in expansion medium until 70% 
confluence was reached. The culture was then shifted to a 
specific induction medium at 37 °C in a humidified incuba-
tor containing 5%  CO2. Thus,  CD117+ cells were cultured in 
‘adipogenic differentiation medium’, ‘osteogenic differentia-
tion medium’ (Lonza, Basel, Switzerland), ‘neurogenic dif-
ferentiation medium’ (PromoCell GmbH, Heidelberg, Ger-
many) or ‘cardiomyogenic differentiation medium’ (Cellular 
Engineering Technologies, Inc., Iowa, USA) for the appro-
priate time according to the manufacturer’s recommended 
protocol. To induce chondrogenic differentiation, a total of 
Table 1  List of antibodies used 
for flow cytometric analysis in 
this study
Antigen Clone Concentration Source of reference
CD14 TUK4 10 µl/2.5 × 105 cell Miltenyi Biotec, Auburn, CA, USA
CD29 AG89 20 µl/2.5 × 105 cell MBL CO., LTD., Nagoya, Japan
CD34 581 20 µl/2.5 × l05 cell BD Bioscience Pharmingen, San Diego, CA, USA
CD73 AD2 20 µl/2.5 × l05 cell BioLegend Inc., San Diego, CA, USA
CD90 5E10 20 µl/2.5 × 105 cell BioLegend Inc., San Diego, CA, USA
HLA-DR B8.12.2 20 µl/2.5 × 105 cell Beckman Coulter, Inc., Brea, CA, USA
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2.5 × 105 cells were placed into a 15-mL conical polypropyl-
ene tube and centrifuged at 1500 rpm for 10 min. Then cell 
pellets (1 pellet/tube) were cultured for 21 days in ‘chondro-
genic differentiation medium’ (Lonza, Basel, Switzerland).
Osteogenesis was assessed by Alizarin staining (Cosmo 
Bio Co., Ltd. Tokyo, Japan) of the calcified extracellular 
matrix deposition. Oil red O staining was used for detection 
of intracellular lipid droplet formation to evaluate adipogen-
esis. Chondrogenic differentiation was determined by Alcian 
Blue staining. For the evaluation of neural differentiation, 
we immunostained cells for the neuron-specific marker 
MAP-2. Differentiation into the cardiomyogenic lineage was 
determined by cardiac troponin T immunostaining. Antibody 
information is listed in Table 2.
Enzyme‑linked immunosorbent assay (ELISA) 
of paracrine mediators secreted from hAFS
hAFS at passages 4–6 were seeded on 35-mm culture 
dishes with amniotic fluid cell culture medium at a density 
of 1 × 105 cells/well. After 72 h, the confluent cells were 
washed with PBS and then incubated in amniotic fluid cell 
culture medium. After another 12 h, 24 h, 48 h and 72 h, the 
medium was collected and designated “conditioned medium 
derived from hAFS”. Paracrine mediator levels for vascular 
endothelial growth factor (VEGF), IL-10 and  PGE2 were 
determined using ELISA kits according to the manufac-
turer’s protocol.
A dorsal excisional cutaneous wound model 
in BALB/c mice
BALB/c mice (8 weeks old; male; body weight, 20–23 g) 
were obtained from Oriental Yeast Co., Ltd. (OYC, Tokyo, 
Japan). To prepare skin defects, mice were anesthetized with 
3% isoflurane followed by maintenance with 2% isoflurane. 
After hair removal from the dorsal surface, 8-mm full-thick-
ness excisional skin wounds were created on each side of the 
midline using a sterile biopsy punch (Kai Industries Co., 
Ltd, Japan). We injected 240 µL PBS (containing or lacking 
1 × 106 hAFS) around the wound at 6 injection sites. Wounds 
were then covered with an occlusive dressing (Tegaderm, 
Sumitomo 3M, Ltd., Tokyo, Japan) and an elastic adhesive 
bandage (Silkytex, ALCARE Co, Ltd., Tokyo, Japan). All 
procedures were performed according to the guidelines for 
the Care and Use of Laboratory Animals of Keio Univer-
sity School of Medicine, and were approved by the Animal 
Study Committee of Keio University (IRB approval number 
15083-(0)).
Macroscopic and histological analyses of cutaneous 
wounds
Mice were killed by atlantoaxial subluxation, and skin with 
the wound was removed. Wound size was macroscopically 
monitored with a microscope camera (Leica, Wetzlar, Ger-
many) 0, 7, 14 and 21 days after the treatment. Wound sizes 
(percentage of wound area to initial wound area) were cal-
culated from the photographs using ImageJ software (http://
www.rsb.info.nih.gov/ij; n = 5 per group).
Skin samples were harvested 0, 7, 14, and 21 days after 
the treatment. Excised specimens were fixed with 4% para-
formaldehyde for paraffin embedding. Paraffin sections 
(4 µm) were treated with H&E, Masson’s Trichrome, Elas-
tica van Gieson and Picrosirius red stains. Immunostain-
ing for α-smooth muscle actin (α-SMA), type I and III col-
lagen was also performed. Antibody information is listed 
in Table 2. Stained sections were viewed by microscopy 
(BZ-9000, KEYENCE, Osaka, Japan), and Picrosirius 
Table 2  List of antibodies used for immunofluorescence staining in this study
Primary antibody Clone Concentration Source of reference
MAP-2 Mouse IgGl 1:100 Sigma-Aldrich, St. Louis, MO, USA
Cardiac troponin T Mouse IgGl 1:100 Thermo Fisher Scientific, Waltham, MA, 
USA
Smooth muscle actin 1A4 1:200 Dako, Carpinteria, CA, USA
Collagen I Rabbit polyclonal 1:200 Abeam, Cambridge, UK
Collagen III Rabbit polyclonal 1:1000 Abeam, Cambridge, UK
Secondary antibody Concentration Source of reference
Goat anti-rabbit IgG Alexa four 488 1:250 Thermo Fisher Scientific, Waltham, 
MA, USA
Goat anti-mouse IgM Alexa four 488 1:250 Thermo Fisher Scientific, Waltham, 
MA, USA
Goat anti-mouse IgG Alexa four 555 1:250 Thermo Fisher Scientific, Waltham, 
MA, USA
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red-stained sections were observed using polarized micros-
copy (BX53-P, Olympus, Tokyo, Japan).
Morphometric analysis of re‑epithelialization 
and formation of granulation tissue 
and myofibroblasts
The width of the wound and the distance of the traversed 
epithelium were measured on Masson’s Trichrome-stained 
sections, and the percentage of the tissue that underwent re-
epithelialization was calculated according to the following 
formula: [distance covered by epithelium]/[distance across 
wound bed] × 100 (n = 5) [15]. The granulation tissue area in 
the wounds was determined on Elastica van Gieson-stained 
sections according to previous methods (n = 5) [15]. Myofi-
broblasts were identified by α-SMA immunostaining, a clas-
sical myofibroblast-specific method.
Assessment of the ability of hAFS to engraft 
in wound
hAFS were labeled with PKH-26 Red fluorescent cell linker 
kit, as per the manufacturer’s protocol (Sigma-Aldrich, St. 
Louis, MO, USA). Cells (1 × 106) were seeded on 35-mm 
culture dishes with serum-free α-MEM. After 24 h, the cells 
were viewed by fluorescent microscopy (BZ-9000, KEY-
ENCE). hAFS labeled with PKH-26 were injected around 
the wound at six injection sites. Each wound received 1 × 106 
cells (hAFS labeled with PKH-26) suspended in 240 µL 
PBS or 240 µL cell-free PBS. Skin samples were harvested 
1, 4, 7, 14 and 21 days after the treatment. Cryosections 
were stained with Hoechst-33342. Fluorescent images 
were captured using a fluorescent microscopy (BZ-9000, 
KEYENCE).
RNA isolation and quantitative real‑time RT‑PCR
Total RNA was isolated with an RNeasy mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instruc-
tion. The total skin RNA underwent reverse transcription 
to cDNA using a Prime Script RT Master Mix (Takara Bio, 
Shiga, Japan). Quantitative PCRs were performed in dupli-
cate in a volume of 25 µL per reaction in a 96-well Bio-Rad 
CFX96 Real-time PCR System (Bio-Rad, Inc., Hercules, 
CA, USA). Reaction mixtures included 5 ng of genomic 
DNA as template, 0.4 mM each primer (Thermo Fisher Sci-
entific Inc., Tokyo, Japan), SYBR Premix Ex Taq II (Tli 
RNaseH Plus) (Takara Bio, Shiga, Japan), and sterile  H2O. 
The primer sets are listed in Table 3. PCR was performed 
as follows: pre-denaturation at 95 °C for 30 s, 45 cycles of 
denaturation at 95 °C for 5 s, annealing at 60 °C for 20 s. 
The negative control (without reverse transcriptase) had no 
signal. The relative level of gene expression for each sam-
ple was calculated using the  2−ΔΔCT method. Gene expres-
sion levels were normalized to that of Gapdh as an internal 
control.
Statistical analysis
All results are expressed as means ± SD. The quantitative 
variable was statistically analyzed using a one-way ANOVA 
followed by a Student’s t test. P < 0.05 was considered statis-
tically significant. Each analysis was performed with com-
mercially available software (IBM SPSS Statistics 24).
Results
Isolation, culture and immunophenotypic 
characterization of  CD117+ amniotic fluid cells
Isolated amniotic fluid cells consisted of a mixed popula-
tion of adherent cells with different morphologies and sizes. 
Most were spindle and round-shaped cells. After immunose-
lection and passage in culture, clonal spindle-shaped cells 
were expanded as stable lines (Fig. 1a). The cell-surface 
antigenic expression of  CD117+ amniotic fluid cells was 
determined flow cytometrically.  CD117+ amniotic fluid cells 
were strongly positive for mesenchymal markers, such as 
CD29, CD73, and CD90, whereas they were negative for 
hematopoietic markers such as CD14, CD34, and HLA-DR 
(Fig. 1b). We also determined the differentiation capability 
Table 3  List of primer sequence used in this study
Gene name Amplicon 
length (bp)
Forward primer sequences (5′–3′) Reverse primer sequences (5′–3′)
Collagen, type I. alpha 1 (Col1a1) 145 ACT GGT ACA TCA GCC CGA ACC GAC ATT AGG CGC AGG AAG GTC 
Collagen, type I, alpha 2 (Col1a2) 147 CAG GCC CAA CCT GTA AAC ACC CTG AGT TGC CAT TTC CTT GGAG 
Collagen, type III, alpha 1 (Col3a1) 170 CCA TGA CTG TCC CAC GTA AGC CCG GCT GGA AAG AAG TCT GAG 
α-Smooth muscle actin (Acta2) 156 CAG GCA TGG ATG GCA TCA ATCAC ACT CTA GCT GTG AAG TCA GTG TCG 
Glyceraldehyde-3-phosphate dehydro-
genase (Gapdh)
87 TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 
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Fig. 1  Isolation, culture, and 
immunophenotypic charac-
terization of  CD117+ amniotic 
fluid cells. a A bright-field 
image shows the morphology 
of  CD117+ amniotic fluid cells 
in culture. Scale bar = 100 µm. 
b  CD117+ amniotic fluid cells 
were stained with antibodies 
and analyzed by flow cytometry. 
c–e Representative microscopic 
images of  CD117+ amniotic 
fluid cells. The cells were 
cultured with adipogenic, osteo-
genic or chondrogenic differ-
entiation media for appropriate 
times, and they were assessed 
by Oil red O (c), Alizarin red 
(d) or Alcian blue (e) staining. 
Scale bar = 50 µm. f Cardiomy-
ogenic lineage-specific signals 
observed after cardiac troponin 
T staining. g Neuron lineage-
specific signals exhibited after 
MAP-2 staining. h ELISA 
analysis of paracrine media-
tors secreted from  CD117+ 
amniotic fluid cells. Images are 
representative of 3 independent 
experiments performed with 
cells from different donors
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of  CD117+ amniotic fluid cells. These cells could differ-
entiate towards adipogenic, osteogenic and chondrogenic 
lineages, as shown by Oil red O, Alizarin red, and Alcian 
blue staining, respectively (Fig. 1c–e). We evaluated the 
differentiation potential toward neuronal lineages and car-
diomyogenic lineages. As expected, we observed the pres-
ence of cells that expressed MAP-2 as a neuronal marker 
(Fig. 1f) and cardiac troponin T as a cardiomyogenic marker 
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(Fig. 1g). Based on these results,  CD117+ amniotic fluid 
cells were shown to fulfill the minimal criteria of an MSC 
population [16] with potentials for neuronal and cardiomyo-
genic differentiation, as previously reported [12, 13, 17, 18].
Paracrine mediators secreted from hAFS
To determine the molecular mediators secreted from hAFS, 
we used ELISA assays to examine conditioned medium 
derived from hAFS. ELISAs showed that VEGF levels 
gradually increased during the observation period, whereas 
IL-10 and  PGE2 levels peaked at 12 h and declined to base-
line (Fig. 1h).
hAFS treatment transiently accelerated cutaneous 
wound closure by enhancing re‑epithelialization 
of the epidermis without affecting the granulation 
tissue area in the dermis
To investigate whether hAFS treatment affected wound 
healing, we injected hAFS or PBS (control) around 8-mm 
full-thickness excisional skin wounds created on the backs 
of BALB/c mice. Macroscopic measurement of wound size 
demonstrated that hAFS treatment significantly accelerated 
wound closure compared to control (Fig. 2a). Accelera-
tion of wound closure in hAFS groups was observed up to 
day 14, but there was no obvious difference between the 
2 groups at day 21 (Fig. 2a). Additionally, an analysis of 
re-epithelialization in the epidermis measured on Mas-
son’s Trichrome-stained sections demonstrated that hAFS 
treatment significantly enhanced re-epithelialization after 
14 days of treatment compared to control (Fig. 2b). Nev-
ertheless, the granulation tissue area in the dermis meas-
ured on Elastica van Gieson-stained sections did not show 
any difference between the 2 groups during the observation 
period (Fig. 2c). These results indicated that hAFS treat-
ment accelerated cutaneous wound closure by enhancing 
re-epithelialization in the epidermis without affecting the 
granulation tissue area in the dermis compared to controls.
hAFS decreased α‑SMA expression in regenerated 
dermal tissues
In mice, the skin contraction induced by α-SMA-positive 
myofibroblasts as well as skin tissue generation contributes 
to cutaneous wound closure [1, 19]. To investigate whether 
skin contraction affected wound closure, we evaluated 
α-SMA-positive cells in granulation tissue. We found that 
hAFS significantly decreased α-SMA-positive expression by 
myofibroblasts compared to controls (Fig. 3a, b). In addition, 
quantitative real-time PCR analysis also showed a significant 
reduction in mRNA levels of α-SMA at day 14 in the hAFS 
group compared to controls (Fig. 3c). These observations 
suggested that hAFS regulated the rate of fibroblast differen-
tiation into α-SMA-positive myofibroblasts at the transcrip-
tional level. Taken together, we confirmed that hAFS injec-
tion accelerated cutaneous wound closure independently of 
wound contraction.
hAFS treatment attenuated fibrotic changes 
in the regenerated wound
Myofibroblasts containing α-SMA protein play a central 
role in synthesizing fibrotic tissue containing excess type I 
collagen [1, 19]. Fibrotic scarring is the final consequence 
of wound healing and determines its quality. To investigate 
fibrotic scarring of the regenerated wound, we histologically 
examined collagen organization in regenerated wounds at 
day 21. Picrosirius red staining showed that type I collagen 
(red and yellow) bundle organization was markedly reduced 
and type III collagen (green) was increased in hAFS groups 
(Fig. 4a). As the ratio between type I collagen and type III 
collagen protein expression during wound healing repre-
sents a valuable indicator for tissue fibrosis [2, 5], we inves-
tigated type I and type III collagen expression in regenerated 
wounds at day 21. Although type I collagen expression was 
comparable between the 2 groups, type III collagen protein 
expression was markedly increased in hAFS groups com-
pared to control (Fig. 4b). Furthermore, quantitative real-
time PCR analysis showed an increase in mRNA levels for 
type III collagen during the observation period (Fig. 4c). 
There was an especially significant increase at day 14 in 
the hAFS group, although mRNA levels for type I collagen 
were comparable between the 2 groups except for a signifi-
cant decrease Col1a1 at day 7 in the hAFS group (Fig. 4c). 
These findings suggested that hAFS treatment exerted anti-
fibrotic effects resembling fetal wound healing, which were 
Fig. 2  hAFS treatment enhanced cutaneous wound closure by accel-
erating re-epithelialization without affecting granulation tissue. a 
Representative images of full-thickness excisional wounds treated 
with phosphate-buffered saline (PBS), or 1.0 × 106 hAFS 0, 7, 14 and 
21 days after the treatment (left). Data expressed as the percentage 
of the initial wound size at day 0 (right). b Representative images 
of Masson’s Trichrome staining section  14 days after the treatment 
[wound margin (arrows) and the leading edge of the epithelia (arrow-
heads)] (n = 5). The percentage of re-epithelialization was calculated 
according to the following formula: [distance covered by epithelium: 
distance between wound margin (arrow) − distance between the lead-
ing edge of epithelia (arrowheads)]/[distance between wound margin 
(arrow)] × 100. Scale bar = 500  µm (upper), 100  µm (lower). c Rep-
resentative images of Elastica van Gieson-stained sections 14 days 
after hAFS treatment. Dotted line shows the granulation tissue area. 
Quantification of granulation tissue areas after 0, 7, 14 and 21 days 
by the morphometric evaluation of granulation tissue area measured 
on Elastica van Gieson-stained sections (n = 5). Scale bar = 500  µm 
(upper), 100  µm (lower). Results are presented as mean ± SD. 
*P < 0.05 and **P < 0.01 compared to control
◂
58 M. Fukutake et al.
1 3
characterized by higher type III collagen expression regu-
lated at the transcriptional level.
hAFS transiently engrafted in the wound
The ability of hAFS to engraft in a wound was assessed by 
hAFS labeled with PKH-26. We confirmed that hAFS could 
be labeled with PKH-26 in vitro by mixing cells with PKH-
26 on culture dishes followed by 24-h cultivation. The cells 
were then assayed by fluorescent microscopy. This study 
clearly demonstrated that hAFS could be labeled with PKH-
26 (Fig. 5a). To investigate the ability of hAFS to engraft in the 
wound, skin samples harvested after injection of hAFS labeled 
with PKH-26 were examined. At day 1 and day 4, large num-
bers of hAFS were observed both in the epidermis and dermis. 
However, after day 7, hAFS were mainly observed in the epi-
dermis but not the dermis. At day 21, no labeled cells could be 
detected in the wound (Fig. 5b). Moreover, we also performed 
Fig. 3  hAFS treatment inhibited 
α-SMA-positive myofibroblast 
formation. a Representative 
images of treated regener-
ated wounds using antibodies 
against myofibroblast-specific 
marker α-SMA on days 7, 14 
and 21. Scale bar = 500 µm. b 
Morphometric analysis of the 
α-SMA-positive area. Results 
are presented as means ± SD 
(n = 3). *P < 0.05 compared to 
control. c Quantitative real-time 
PCR of α-SMA expression 
levels on days 7, 14 and 21 
(n = 3). Results are presented 
as means ± SD. *P < 0.05 com-
pared to control
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immunohistochemical analysis to determine the localization 
of human-derived cells using anti-human mitochondria anti-
bodies (Supplemental Fig. 1). In accordance with the results 
of PKH26 analysis, human-derived cells could be observed 
at days 1, 4, 7, and 14. However, no labeled cells could be 
detected in the wound at day 21. These results suggested that 
hAFS transplanted into the epidermis might accelerate wound 
closure via enhancement of re-epithelialization through direct 
differentiation into epidermal cells (such as keratinocytes) and 
through paracrine mechanisms. In contrast, hAFS in the der-
mis might alter collagen organization by paracrine signaling, 
not by direct differentiation into dermal cells.
Fig. 4  hAFS treatment altered 
collagen organization in the 
regenerated tissues 21 days after 
treatment. a Representative 
images of regenerated tissue 
stained with Picrosirius red 
using optical (upper) and polar-
ized light microscopy (lower) 
at day 21. The alignment of 
type I collagen (yellow and red) 
and type III collagen (green) 
was observed by polarized 
microscopy (lower). Scale 
bars = 1 mm (upper), 50 µm 
(lower). b Representative 
immunofluorescent stains of 
the regenerated tissue at day 
21 using antibodies against 
type I (left) and type III (right) 
collagen, followed by Hoechst 
staining. Scale bars = 100 µm. 
c Quantitative real-time PCR 
of Col1a1, Col1a2, and Col3a1 
expression levels at days 7, 
14 and 21 (n = 3). Images are 
representative of 3 independent 
experiments. Results are pre-
sented as means ± SD. *P < 0.05 
compared to control
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Discussion
In the present study, we demonstrated that hAFS have a 
unique potential to accelerate cutaneous wound healing 
with less fibrotic scarring, thereby resembling fetal wound 
healing.
MSCs have demonstrated an ability to modulate the 
wound environment to accelerate wound closure [9–11]. 
In our study, hAFS treatment accelerated cutaneous wound 
closure by enhancing re-epithelialization for up to 14 days. 
Moreover, hAFS, which could differentiate into an ectoder-
mal lineage, were engrafted in the epidermis during this 
Fig. 5  Engraftment of hAFS 
in wound. a Representative 
images of hAFS labeled with 
PKH-26 in vitro (red). Cells 
were stained with Hoechst. 
Scale bar = 50 µm. b Immuno-
fluorescent and Hoechst staining 
of the cutaneous tissues 1, 7, 
14 and 21 days after injection 
of hAFS labeled with PKH-26. 
Scale bar = 200 µm. Images are 
representative of 3 independent 
experiments
a 
Day1 
Day21 
Day14 Day7 
Day4 
b 
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period. In the literature, there is considerable debate over 
the mechanisms by which MSCs promote cutaneous wound 
healing. Although it appears to be partially due to direct 
differentiation into epidermal cells and keratinocytes [20], 
paracrine signaling, such as the release of trophic factors that 
promote angiogenesis, immunomodulation, and recruitment 
of endogenous tissue stem cells, has been suggested as pos-
sible mechanism underlying the effects of MSCs in wound 
healing [9, 11, 21]. Among MSCs, hAFS and their condi-
tioned medium have been reported to promote wound clo-
sure by direct differentiation into keratinocytes and through 
paracrine signaling via the TGF-β/SMAD2 pathway [20, 
22]. We suggest that both direct differentiation and paracrine 
effects contribute to wound closure in our study [20, 22].
Murine full-thickness wounds close through re-epitheli-
alization and through α-SMA-positive myofibroblast-driven 
contraction in granulation tissue. In granulation tissue, fibro-
blasts constitute the main cell population. They are present 
in the dermis, proliferate rapidly, and migrate to wound sites 
and differentiate into myofibroblast due to stimulation by 
growth factors such as transforming growth factor-β in the 
wound. The continued presence and activation of myofibro-
blasts during wound regeneration induce fibrotic scarring [1, 
2, 4, 5, 7, 19, 23]. In the present study, we found that hAFS 
treatment suppressed α-SMA-positive myofibroblast expres-
sion at the transcriptional level in the dermis, implying that 
hAFS improves the quality of ECM remodeling and accel-
erates wound closure independent of wound contraction by 
regulating fibroblast differentiation into myofibroblast that 
is the major determinant for fibrotic scarring in the regen-
erating tissue.
Few studies have focused on the anti-fibrotic effect of 
MSCs on ECM remodeling during wound healing. Their 
potential for reduced fibrotic scarring is less well estab-
lished in vivo, as a result of sometimes conflicting findings 
[21, 24–32]. To the best of our knowledge, this is the first 
study focusing on the anti-fibrotic effect of hAFS treat-
ment on ECM remodeling during wound healing. We found 
that hAFS treatment had anti-fibrotic effects in the dermis, 
thereby resembling fetal wound healing. Healing was char-
acterized by higher expression of type III collagen at the 
transcriptional level, which was followed by a significant 
decrease of α-SMA-positive myofibroblasts. There are phe-
notypic differences between the collagen contents in fetal 
and adult wounds. In adults, after exposure to inflamma-
tory mediators in wounds, dermal fibroblasts differentiate 
into myofibroblasts that express excessive type I collagen, 
leading to scar formation. On the other hand, fetal dermal 
fibroblasts before 18 days of gestation in mice and 24 weeks 
of gestations in humans synthesize more type III collagen, 
leading to scar-free fetal wound healing [2–6]. Our data sug-
gest that hAFS cells regulate fibroblast differentiation result-
ing in improved ECM remodeling during wound healing. 
This might be achieved by converting dermal fibroblasts into 
fetal-like fibroblasts (not to myofibroblast of adult charac-
ter), resulting in less fibrotic scarring.
MSCs possess a number of trophic functions that modu-
late fibrotic scarring [29]. In the present study, paracrine 
factors secreted from hAFS transiently engrafted in the 
dermis during the inflammatory phase (i.e., at days 1 and 
4) might play a pivotal role in regulating fibroblast phe-
notype. Notably, IL-10 and  PGE2, both of which were 
observed in the hAFS secretome in our study, are potent 
mediators that inhibit inflammatory and fibrotic responses 
by regulating fibroblast phenotype during wound healing 
[33–36]. Although further investigation is needed to eluci-
date the detailed mechanisms by which the hAFS secretome 
regulates fibroblast differentiation and thereby enhances 
ECM remodeling during wound healing, our results sug-
gest that hAFS regulate fibroblast differentiation and exert 
anti-fibrotic effects on wound healing through a paracrine 
mechanism.
In vivo therapeutic potential of MSCs depends on its 
source [37]. The limitation of the study was that we did 
not compare the anti-fibrotic effect of hAFS on cutaneous 
wound healing with other MSCs derived from bone marrow 
(BM) and adipose tissue. However, in the present study, we 
directly compared IL-10 and PGE2 secretions derived from 
hAFS and BM-MSCs under the same conditions in vitro 
(Supplemental Fig. 2). Interestingly, IL-10 concentration 
was comparable between hAFS group and BM-MSC group. 
However, PGE 2 was significantly higher in the BM-MSC 
group cultured over 24 h compared to hAFS. These results 
indicated the difference of immune responses between 
hAFS and BM-MSCs, suggesting that we need to compare 
the anti-fibrotic effect of hAFS in vivo with other MSCs. 
Doi et al. recently described that the therapeutic effect of 
MSCs derived from umbilical cord blood and Wharton’s 
jelly on cutaneous wound healing were comparable [38]. 
As to hAFS, we would like to address this question using 
in vivo studies in future investigations.
Amniotic fluid contains cells derived from developing 
fetal tissues, including fetal skin [13]. These cells might pro-
mote cutaneous wound healing because the factors respon-
sible for scarless fetal wound healing have been attributed 
to the developing fetal tissue itself [2, 3, 6]. Therefore, it 
is reasonable that hAFS could have significant anti-fibrotic 
potential for cutaneous wound healing. In other words, our 
findings suggest that hAFS could contribute to fetal scarless 
wound healing as suggested by recent studies [3, 8].
hAFS cells offer intriguing potentials for autologous stem 
cell treatment for a variety of complications in neonates, 
including congenital abnormalities and preterm birth. To 
prepare an adequate amount of autologous hAFS for these 
neonates, only a small amount of amniotic fluid cells col-
lected by amniocentesis is required, with minimal invasive 
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risk for the patient. hAFS have an anti-fibrotic potential for 
treatment of intractable perinatal diseases and can target 
various organs, including lung [39, 40], kidney [41–44] and 
liver [45] as well as cutaneous wounds. Thus, anti-fibrotic 
treatment by hAFS could be a promising autologous stem 
cell therapy for intractable perinatal diseases.
Conclusion
Our study provides evidence that hAFS have a unique poten-
tial to accelerate cutaneous wound healing with reduced 
fibrotic scarring. Anti-fibrotic treatment using hAFS could 
be a promising autologous stem cell therapy for intractable 
perinatal diseases.
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